These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 35593174

  • 1. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
    Signorelli F, Balbi GGM, Aikawa NE, Silva CA, Kupa LVK, Medeiros-Ribeiro AC, Yuki EF, Pasoto SG, Saad CG, Borba EF, Seguro LPC, Pedrosa T, Oliveira VAA, Costa ALCS, Ribeiro CT, Santos REB, Andrade DCO, Bonfá E.
    Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
    [Abstract] [Full Text] [Related]

  • 2. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
    Shinjo SK, de Souza FHC, Borges IBP, Dos Santos AM, Miossi R, Misse RG, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, Kupa LVK, Ceneviva C, Seraphim JC, Pedrosa TN, Vendramini MBG, Silva CA, Aikawa NE, Bonfá E.
    Rheumatology (Oxford); 2022 Aug 03; 61(8):3351-3361. PubMed ID: 34664616
    [Abstract] [Full Text] [Related]

  • 3. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
    Pasoto SG, Halpern ASR, Guedes LKN, Ribeiro ACM, Yuki ENF, Saad CGS, da Silva CAA, de Vinci Kanda Kupa L, Villamarín LEB, de Oliveira Martins VA, Martins CCMF, Deveza GBH, Leon EP, Bueno C, Pedrosa TN, Santos REB, Soares R, Aikawa NE, Bonfa E.
    Clin Rheumatol; 2022 Jul 03; 41(7):2079-2089. PubMed ID: 35306594
    [Abstract] [Full Text] [Related]

  • 4. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
    Yuki EFN, Borba EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Medeiros-Ribeiro AC, Silva CA, de Andrade DCO, Kupa LVK, Betancourt L, Bertoglio I, Valim J, Hoff C, Formiga FFC, Pedrosa T, Kallas EG, Aikawa NE, Bonfa E.
    Arthritis Care Res (Hoboken); 2022 Apr 03; 74(4):562-571. PubMed ID: 34806342
    [Abstract] [Full Text] [Related]

  • 5. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
    Araujo CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Silva MSR, Yuki EFN, Pasoto SG, Pedrosa T, Kupa LVK, Zou G, Pereira RMR, Silva CA, Aikawa NE, Bonfa E.
    Ann Rheum Dis; 2022 Jun 03; 81(6):889-897. PubMed ID: 35193873
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
    Pereira RMR, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EFN, Saad CGS, Medeiros-Ribeiro AC, Kupa LVK, Fusco SRG, Martins VAO, Martins CCMF, Barbas CV, Shinjo SK, Aikawa NE, Bonfa E.
    Clinics (Sao Paulo); 2023 Jun 03; 78():100150. PubMed ID: 36529052
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.
    Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, Rojo PT, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Ribeiro CT, Deveza GBH, Martins VAO, Silva CA, Lopes MH, Duarte AJS, Antonangelo L, Sabino EC, Kallas EG, Pasoto SG, Bonfa E.
    Nat Med; 2021 Oct 03; 27(10):1744-1751. PubMed ID: 34331051
    [Abstract] [Full Text] [Related]

  • 10. COVID-19 vaccine affects neither prothrombotic antibody profile nor thrombosis in primary anti-phospholipid syndrome: a prospective study.
    Pan H, Tang Z, Teng J, Sun Y, Liu H, Cheng X, Su Y, Ye J, Hu Q, Chi H, Zhou Z, Jia J, Meng J, Wang M, Wang F, Chen X, Ma Y, Zhang H, You Y, Zhu D, Chen L, Yang C, Shi H, Liu T.
    Rheumatology (Oxford); 2023 Feb 01; 62(2):829-834. PubMed ID: 35866674
    [Abstract] [Full Text] [Related]

  • 11. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases.
    Gatto M, Perricone C, Tonello M, Bistoni O, Cattelan AM, Bursi R, Cafaro G, De Robertis E, Mencacci A, Bozza S, Vianello A, Iaccarino L, Gerli R, Doria A, Bartoloni E.
    Clin Exp Rheumatol; 2020 Feb 01; 38(4):754-759. PubMed ID: 32723434
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The APSANTICO Study: A Prospective Observational Study to Evaluate Antiphospholipid Antibody Profiles in Patients with Thromboembolic Antiphospholipid Syndrome (APS) after COVID-19 Infection and/or Vaccination.
    Ott O, Herrmann E, Schulz A, Lindhoff-Last E.
    Int J Mol Sci; 2023 Mar 15; 24(6):. PubMed ID: 36982716
    [Abstract] [Full Text] [Related]

  • 14. Antiphospholipid antibodies are enriched post-acute COVID-19 but do not modulate the thrombotic risk.
    Emmenegger M, Emmenegger V, Shambat SM, Scheier TC, Gomez-Mejia A, Chang CC, Wendel-Garcia PD, Buehler PK, Buettner T, Roggenbuck D, Brugger SD, Frauenknecht KBM.
    Clin Immunol; 2023 Dec 15; 257():109845. PubMed ID: 37995947
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal Analysis of Antiphospholipid Antibody Dynamics after Infection with SARS-CoV-2 or Vaccination with BNT162b2.
    Ogrič M, Žigon P, Sodin-Semrl S, Zlatković-Švenda M, Zdravković M, Ovuka M, Švec T, Lakota K, Radšel P, Rotar Ž, Čučnik S.
    Int J Mol Sci; 2022 Dec 22; 24(1):. PubMed ID: 36613655
    [Abstract] [Full Text] [Related]

  • 16. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
    Netto LC, Ibrahim KY, Picone CM, Alves APPS, Aniceto EV, Santiago MR, Parmejani PSS, Aikawa NE, Medeiros-Ribeiro AC, Pasoto SG, Yuki EFN, Saad CGS, Pedrosa T, Lara AN, Ceneviva C, Bonfa E, Kallas EG, Avelino-Silva VI.
    Lancet HIV; 2022 May 22; 9(5):e323-e331. PubMed ID: 35338835
    [Abstract] [Full Text] [Related]

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M, Unal S.
    Trials; 2021 Apr 13; 22(1):276. PubMed ID: 33849629
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S, Traiyan S, Yorsaeng R, Vichaiwattana P, Sudhinaraset N, Wanlapakorn N, Poovorawan Y.
    J Med Virol; 2022 Apr 13; 94(4):1442-1449. PubMed ID: 34783049
    [Abstract] [Full Text] [Related]

  • 19. Cardiac manifestations in primary antiphospholipid syndrome and their association to antiphospholipid antibodies' types and titers-cross-sectional study of Serbian cohort.
    Djokovic A, Stojanovich L, Stanisavljevic N, Djokic S, Filipovic B, Matic P, Milanovic M, Apostolovic S, Saponjski J.
    Clin Rheumatol; 2022 May 13; 41(5):1447-1455. PubMed ID: 35018582
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P, Guo X, Chen W, Ma S, Pan H, Dai L, Du P, Wang L, Jin L, Chen Y, Shi F, Liu J, Xu X, Zhang Y, Gao GF, Chen C, Feng J, Li J, Zhu F.
    PLoS Med; 2022 May 13; 19(5):e1003953. PubMed ID: 35617368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.